LGND News and Press, Ligand Pharmaceuticals Incorporated From 08/08/22

Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and progr...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units (&...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will i...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jason Haas to the Company's Board of Directors. Mr. Haas brings more than 30 years of healthcare investment banking and corporate finance exper...

The American Society of Clinical Oncology (ASCO) held its annual meeting this week, and it's a must-show event for anybody pursuing cancer therapies. Our mini-roundtable has been digging into some of the presentations, and we found a few companies announcing nice surprises, among them, Ad...

COLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1 -mutated metastatic breast and gynecological cancers, today announced that it will host a virtual upd...

While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but something special is hidden underneath. Those looking to get in before the story plays o...

Ligand Pharmaceuticals Incorporated (LGND) Q1 2022 Earnings Conference Call May 04, 2022 04:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - CEO Matt Foehr - COO Matt Korenberg - CFO Conference Call Participants Larry Solow - CJS Securities Matt Hewitt -...

Ligand Pharmaceuticals press release (NASDAQ:LGND): Q1 Non-GAAP EPS of $0.76 beats by $0.10. Revenue of $45.69M (-17.2% Y/Y) beats by $11.48M. Outlook: Ligand is reaffirming 2022 revenue guidance for the combined business and providing revenue estimated to be attributable to the OmniAb busine...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conf...